EMMA · Emmaus Life Sciences, Inc.
$0.03
+0.01 (+22.99%)
At close · Aug 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because the Company's existing cash balance and anticipated cash flows cannot satisfy its current debt and ongoing obligations, combined with the uncommitted nature of the Company's financing plans, there is substantial doubt about the Company’s ability to continue as a going concern for 12 months from the date that these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$2.25M
Shares
70.19M
Volume · Aug 21
847.1K
Avg daily vol (3M)
157.21K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.03
Open$0.03
Day$0.02–0.03
52W close$0.01–0.03
Avg vol 30d172K
Short int3K · 0.0% float · 1.0d
Short vol9%
DataJan 2020–Aug 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$15.53M
Trailing 12 months
Net income (TTM)
−$6.02M
Trailing 12 months
Revenue growth YoY
+124.3%
Year over year
Operating margin
29.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$22.18M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+88.7%
Year over year · more shares
Price change (1Y)
+169.7%
Trailing year
Short interest
—
Latest settlement
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+163%
above
Price vs 50-day avg
+179%
above
RSI (14)
89
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+179%
trailing
6-month return
+177%
trailing
YTD return
+147%
this year
Relative strength
+165%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Accumulating
+1 funds added
Insider flow
Accumulating
Net +$15.0K over 90 days · 0% sells
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Fundamentals
Revenue growth
−25%
Y/Y
Gross margin
93%
expanding
EPS growth
−20%
Y/Y
Free cash flow
$-12.0K
Balance sheet
$25.0M
net debt
Quant / Vol
risk profile
Volatility
222%
annualized · 1-yr
Max drawdown
−82%
past year
ATR
12.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+163%
Bullish
Price vs 50-day avg
+179%
Bullish
RSI (14)
89
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Accumulating
+1 funds added
Insider flow
Accumulating
Net +$15.0K over 90 days · 0% sells
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0
Now $0 · 100%
Range high $0
vs 200-day avg +163%
vs 50-day avg +179%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EMMA
this stock
Emmaus Life Sciences, Inc.
|
$2.25M | +146.9% | -25.2% | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
1
- % held
- 0.1%
- Net QoQ
- +57.0K sh
- Top holder
- Diametric Capital, LP
Held
Float
Short & Settlement
Smart Money
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EMMA | +179.1% | +179.1% | +176.7% | +221.0% | +146.9% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +180.5% | +175.5% | +165.2% | +218.5% | +134.6% |